Article
04 Jun 2026
Polpharma And Tuteur Enter License For The Commercialization Of A Biosimilar Targeting Autoimmune Diseases In Latin America
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
04 May 2026
International Biosimilars Updates
Article
13 Apr 2026
Amgen And Shanghai Henlius/Organon Settle Denosumab BPCIA Litigation
Article
19 Feb 2026
Samsung And Regeneron Settle Aflibercept BPCIA Case
Article
09 Feb 2026
FDA Issues Guidance On Modernizing Statistical Methods For Clinical Trials
Article
22 Jan 2026
Year In Review: Top Legal Developments Of 2025
Article
31 Dec 2025
Biocon And Regeneron Enter Global Settlement On Aflibercept Biosimilar
Article
31 Dec 2025
FDA Approves MAbxience And Amneal's Denosumab Biosimilars
Article
26 Nov 2025
Sandoz And EirGenix Enter Licensing Agreement To Commercialize Proposed Pertuzumab Biosimilar
Article
20 Nov 2025
FDA Approves Shanghai Henlius's Interchangeable Pertuzumab Biosimilar
Article
04 Nov 2025
Teva And Prestige Biopharma Enter Licensing Agreement To Commercialize Their Trastuzumab Biosimilar
Article
04 Nov 2025
FDA Approves Genentech's GAZYVA® (Obinutuzumab)
Article
16 Oct 2025
FDA Approves Celltrion's Aflibercept Biosimilar
Article
15 Sep 2025
Sandoz And Regeneron Settle Aflibercept BPCIA Case
Article
14 Aug 2025
Final Judgment Of Non-Infringement Entered In Alnylam V. Pfizer Vaccine Patent Dispute
Article
30 May 2025
FDA Approves Bio-Thera And Hikma's Ustekinumab Biosimilar
Article
07 May 2025
District Of New Jersey Denies Preliminary Injunction In Ustekinumab Breach Of Contract Case
Article
03 Apr 2025
FDA Approves Fresenius's Denosumab Biosimilars
Article
26 Mar 2025
Celltrion Launches STEQEYMA® (ustekinumab-stba) In The United States
Article
25 Mar 2025
DC Circuit Holds That AI Cannot Be An Author Under Copyright Law